Ensuring Patient Access to Critical Breakthrough Products Act

HR5343, the 'Ensuring Patient Access to Critical Breakthrough Products Act', advanced out of the House Ways & Means Committee on 2025-09-17 with a bipartisan 37-3 vote. It amends Section 1862(a)(1) of the Social Security Act to create a mandatory 4-year transitional Medicare coverage period for any device designated as 'breakthrough' by the FDA. This removes the current discretion CMS has to delay coverage decisions for new technologies, which historically can take 1-3 years after FDA approval. The bill authorizes ZERO direct funding — it is a regulatory mandate, not an appropriation. The mechanism is a coverage requirement: CMS must furnish coverage during the transitional period unless the Secretary finds based on clinical data that the device presents an undue risk of harm outweighing potential benefits. This is a bipartisan legislative fix to a well-documented 'valley of death' between FDA clearance and Medicare reimbursement. The structural winners are medical device manufacturers with large R&D pipelines of breakthrough-designated products: Medtronic ($MDT), Abbott Laboratories ($ABT), Johnson & Johnson ($JNJ), Intuitive Surgical ($ISRG), and Becton Dickinson ($BDX). These companies absorb the costs of FDA breakthrough designation (expedited review) but previously faced no guarantee of near-term Medicare revenue. The bill converts a regulatory approval into effectively immediate revenue eligibility for 4 years. Real market data shows these stocks are in a significant 30-day drawdown: MDT -8.17%, ABT -11.03%, JNJ -6.26%, ISRG -1.75%, BDX -7.3%. MDT is trading at $79.57, near its 52-week low of $78.91. ABT at $91.35 is just above its 52-week low of $90.72. This price weakness appears macro-driven (broader healthcare sell-off) rather than company-specific, creating a potential entry catalyst if the bill gains floor momentum. Legislative timeline: bill must pass the House floor (majority vote), then the Senate, then be signed by the President. The 37-3 committee vote suggests strong bipartisan support. 45 cosponsors, including 6 original cosponsors (Moore, DelBene, Yakym, Sewell, Bilirakis, Trahan), span both parties. No explicit opposition statements surfaced in committee. The bill is likely to be included in a healthcare package or passed by suspension of the rules, though with the 119th Congress now over halfway through, floor time allocation remains uncertain.